Cargando…

Purinergic modulation of microglial cell activation

Microglial cells are resident macrophages in the brain and their activation is an important part of the brain immune response and the pathology of the major CNS diseases. Microglial activation is triggered by pathological signals and is characterized by morphological changes, proliferation, phagocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Sperlágh, Beáta, Illes, Peter
Formato: Texto
Lenguaje:English
Publicado: Springer Netherlands 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2096753/
https://www.ncbi.nlm.nih.gov/pubmed/18404425
http://dx.doi.org/10.1007/s11302-006-9043-x
_version_ 1782138264301338624
author Sperlágh, Beáta
Illes, Peter
author_facet Sperlágh, Beáta
Illes, Peter
author_sort Sperlágh, Beáta
collection PubMed
description Microglial cells are resident macrophages in the brain and their activation is an important part of the brain immune response and the pathology of the major CNS diseases. Microglial activation is triggered by pathological signals and is characterized by morphological changes, proliferation, phagocytosis and the secretion of various cytokines and inflammatory mediators, which could be both destructive and protective for the nervous tissue. Purines are one of the most important mediators which regulate different aspects of microglial function. They could be released to the extracellular space from neurons, astrocytes and from the microglia itself, upon physiological neuronal activity and in response to pathological stimuli and cellular damage. Microglial activation is regulated by various subtypes of nucleotide (P2X, P2Y) and adenosine (A(1), A(2A) and A(3)) receptors, which control ionic conductances, membrane potential, gene transcription, the production of inflammatory mediators and cell survival. Among them, the role of P2X(7) receptors is especially well delineated, but P2X(4), various P2Y, A(1), A(2A) and A(3) receptors also powerfully participate in the microglial response. The pathological role of microglial purine receptors has also been demonstrated in disease models; e.g., in ischemia, sclerosis multiplex and neuropathic pain. Due to their upregulation and selective activation under pathological conditions, they provide new avenues in the treatment of neurodegenerative and neuroinflammatory illnesses.
format Text
id pubmed-2096753
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-20967532008-02-27 Purinergic modulation of microglial cell activation Sperlágh, Beáta Illes, Peter Purinergic Signal Review Microglial cells are resident macrophages in the brain and their activation is an important part of the brain immune response and the pathology of the major CNS diseases. Microglial activation is triggered by pathological signals and is characterized by morphological changes, proliferation, phagocytosis and the secretion of various cytokines and inflammatory mediators, which could be both destructive and protective for the nervous tissue. Purines are one of the most important mediators which regulate different aspects of microglial function. They could be released to the extracellular space from neurons, astrocytes and from the microglia itself, upon physiological neuronal activity and in response to pathological stimuli and cellular damage. Microglial activation is regulated by various subtypes of nucleotide (P2X, P2Y) and adenosine (A(1), A(2A) and A(3)) receptors, which control ionic conductances, membrane potential, gene transcription, the production of inflammatory mediators and cell survival. Among them, the role of P2X(7) receptors is especially well delineated, but P2X(4), various P2Y, A(1), A(2A) and A(3) receptors also powerfully participate in the microglial response. The pathological role of microglial purine receptors has also been demonstrated in disease models; e.g., in ischemia, sclerosis multiplex and neuropathic pain. Due to their upregulation and selective activation under pathological conditions, they provide new avenues in the treatment of neurodegenerative and neuroinflammatory illnesses. Springer Netherlands 2006-12-19 2007-03 /pmc/articles/PMC2096753/ /pubmed/18404425 http://dx.doi.org/10.1007/s11302-006-9043-x Text en © Springer Science + Business Media B.V. 2006
spellingShingle Review
Sperlágh, Beáta
Illes, Peter
Purinergic modulation of microglial cell activation
title Purinergic modulation of microglial cell activation
title_full Purinergic modulation of microglial cell activation
title_fullStr Purinergic modulation of microglial cell activation
title_full_unstemmed Purinergic modulation of microglial cell activation
title_short Purinergic modulation of microglial cell activation
title_sort purinergic modulation of microglial cell activation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2096753/
https://www.ncbi.nlm.nih.gov/pubmed/18404425
http://dx.doi.org/10.1007/s11302-006-9043-x
work_keys_str_mv AT sperlaghbeata purinergicmodulationofmicroglialcellactivation
AT illespeter purinergicmodulationofmicroglialcellactivation